1
|
Lopresti F, Campora S, Rigogliuso S, Nicosia A, Lo Cicero A, Di Marco C, Tornabene S, Ghersi G, La Carrubba V. Improvement of Osteogenic Differentiation of Mouse Pre-Osteoblastic MC3T3-E1 Cells on Core-Shell Polylactic Acid/Chitosan Electrospun Scaffolds for Bone Defect Repair. Int J Mol Sci 2024; 25:2507. [PMID: 38473755 DOI: 10.3390/ijms25052507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Revised: 02/16/2024] [Accepted: 02/17/2024] [Indexed: 03/14/2024] Open
Abstract
Electrospun hybrid scaffolds composed of synthetic and natural polymers have gained increasing interest in tissue engineering applications over the last decade. In this work, scaffolds composed of polylactic acid electrospun fibers, either treated (P-PLA) or non-treated (PLA) with air-plasma, were coated with high molecular weight chitosan to create a core-shell microfibrous structure. The effective thickness control of the chitosan layer was confirmed by gravimetric, spectroscopic (FTIR-ATR) and morphological (SEM) investigations. The chitosan coating increased the fiber diameter of the microfibrous scaffolds while the tensile mechanical tests, conducted in dry and wet environments, showed a reinforcing action of the coating layer on the scaffolds, in particular when deposited on P-PLA samples. The stability of the Chi coating on both PLA and P-PLA substrates was confirmed by gravimetric analysis, while their mineralization capacity was evaluated though scanning electron microscopy (SEM) and energy-dispersive spectroscopy (EDS) after immersing the scaffolds in simulated body fluids (SBF) at 37 °C for 1 week. Sample biocompatibility was investigated through cell viability assay and SEM analysis on mouse pre-osteoblastic MC3T3-E1 cells grown on scaffolds at different times (1, 7, 14 and 21 days). Finally, Alizarin Red assay and qPCR analysis suggested that the combination of plasma treatment and chitosan coating on PLA electrospun scaffolds influences the osteoblastic differentiation of MC3T3-E1 cells, thus demonstrating the great potential of P-PLA/chitosan hybrid scaffolds for bone tissue engineering applications.
Collapse
Affiliation(s)
- Francesco Lopresti
- Department of Engineering, University of Palermo, RU INSTM, Viale delle Scienze, 90128 Palermo, Italy
| | - Simona Campora
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
| | - Salvatrice Rigogliuso
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
| | - Aldo Nicosia
- Institute for Biomedical Research and Innovation, Italian National Research Council (IRIB-CNR), 90146 Palermo, Italy
| | - Alessandra Lo Cicero
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
| | - Chiara Di Marco
- Department of Engineering, University of Palermo, RU INSTM, Viale delle Scienze, 90128 Palermo, Italy
| | - Salvatore Tornabene
- Department of Engineering, University of Palermo, RU INSTM, Viale delle Scienze, 90128 Palermo, Italy
| | - Giulio Ghersi
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
- Abiel s.r.l, via Enzo ed Elvira Sellerio, 50, 90141 Palermo, Italy
| | - Vincenzo La Carrubba
- Department of Engineering, University of Palermo, RU INSTM, Viale delle Scienze, 90128 Palermo, Italy
- ATeN Center, University of Palermo, Viale delle Scienze, Ed. 18A, 90128 Palermo, Italy
| |
Collapse
|
2
|
La Monica F, Campora S, Ghersi G. Collagen-Based Scaffolds for Chronic Skin Wound Treatment. Gels 2024; 10:137. [PMID: 38391467 PMCID: PMC10888252 DOI: 10.3390/gels10020137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2024] [Revised: 02/02/2024] [Accepted: 02/06/2024] [Indexed: 02/24/2024] Open
Abstract
Chronic wounds, commonly known as ulcers, represent a significant challenge to public health, impacting millions of individuals every year and imposing a significant financial burden on the global health system. Chronic wounds result from the interruption of the natural wound-healing process due to internal and/or external factors, resulting in slow or nonexistent recovery. Conventional medical approaches are often inadequate to deal with chronic wounds, necessitating the exploration of new methods to facilitate rapid and effective healing. In recent years, regenerative medicine and tissue engineering have emerged as promising avenues to encourage tissue regeneration. These approaches aim to achieve anatomical and functional restoration of the affected area through polymeric components, such as scaffolds or hydrogels. This review explores collagen-based biomaterials as potential therapeutic interventions for skin chronic wounds, specifically focusing on infective and diabetic ulcers. Hence, the different approaches described are classified on an action-mechanism basis. Understanding the issues preventing chronic wound healing and identifying effective therapeutic alternatives could indicate the best way to optimize therapeutic units and to promote more direct and efficient healing.
Collapse
Affiliation(s)
- Francesco La Monica
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
| | - Simona Campora
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
| | - Giulio Ghersi
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
| |
Collapse
|
3
|
Massaro M, Ghersi G, de Melo Barbosa R, Campora S, Rigogliuso S, Sànchez-Espejo R, Viseras-Iborra C, Riela S. Nanoformulations based on collagenases loaded into halloysite/Veegum® clay minerals for potential pharmaceutical applications. Colloids Surf B Biointerfaces 2023; 230:113511. [PMID: 37597494 DOI: 10.1016/j.colsurfb.2023.113511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Revised: 08/01/2023] [Accepted: 08/05/2023] [Indexed: 08/21/2023]
Abstract
The design and development of nanomaterials capable of penetrate cancer cells is fundamental when anticancer therapy is involved. The use of collagenase (Col) is useful since this enzyme can degrade collagen, mainly present in the tumor extracellular matrix. However, its use is often limited since collagenase suffers from inactivation and short half-life. Use of recombinant ultrapure collagenase or carrier systems for their delivery are among the strategies adopted to increase the enzyme stability. Herein, based on the more stability showed by recombinant enzymes and the possibility to use them in anticancer therapy, we propose a novel strategy to further increase their stability by using halloysite nanotubes (HNTs) as carrier. ColG and ColH were supramolecularly loaded onto HNTs and used as fillers for Veegum gels. The systems could be used for potential local administration of collagenases for solid tumor treatment. All techniques adopted for characterization showed that halloysite interacts with collagenases in different ways depending with the Col considered. Furthermore, the hydrogels showed a very slow release of the collagenases within 24 h. Finally, biological assays were performed by studying the digestion of a type-I collagen matrix highlighting that once released the Col still possessed some activity. Thus we developed carrier systems that could further increase the high recombinant collagenases stability, preventing their inactivation in future in vivo applications for potential local tumor treatment.
Collapse
Affiliation(s)
- Marina Massaro
- Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Parco d'Orleans II, Ed. 16-17, 90128 Palermo, Italy
| | - Giulio Ghersi
- Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Parco d'Orleans II, Ed. 16-17, 90128 Palermo, Italy.
| | - Raquel de Melo Barbosa
- University of Granada, Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, 18071 Granada, Spain
| | - Simona Campora
- Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Parco d'Orleans II, Ed. 16-17, 90128 Palermo, Italy
| | - Salvatrice Rigogliuso
- Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Parco d'Orleans II, Ed. 16-17, 90128 Palermo, Italy
| | - Rita Sànchez-Espejo
- University of Granada, Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, 18071 Granada, Spain
| | - César Viseras-Iborra
- University of Granada, Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, 18071 Granada, Spain; Andalusian Institute of Earth Sciences, CSIC-UGR, 18100 Armilla, Granada, Spain
| | - Serena Riela
- Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Parco d'Orleans II, Ed. 16-17, 90128 Palermo, Italy.
| |
Collapse
|
4
|
Satragno C, Barboro M, Alparone A, Fiorella G, Turazzi M, Campora S, Cena SE, Coco A, Esposito D, Ferrero A, Ginulla A, Mastrogiovanni S, Piciche F, Scaffidi C, Tominai C, Cavagnetto F, Zefiro D, Giannelli F, Barra S, Belgioia L. An Innovative Approach to Scalp Segmentation in Pediatric Brain Radiotherapy: An Atlas-Based Study. Int J Radiat Oncol Biol Phys 2023; 117:e485-e486. [PMID: 37785534 DOI: 10.1016/j.ijrobp.2023.06.1713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) This study aims to develop an atlas-based method for segmentation of the scalp in pediatric patients that received brain radiotherapy. The study focuses on the development of a model that utilizes CT scans of pediatric medulloblastoma (MB) patients who underwent craniospinal-irradiation (CSI) and a boost in the posterior cranial fossa (PCF). MATERIALS/METHODS A team of experts created the Alopecia_Hope (A_H) contouring protocol on the CT scan using the 2018 EPTN consensus-based atlas and by defining for the manual adjustments the anatomic bone landmarks to differentiate between the scalp and the facial and neck skin. Using RayStation version 12A-SP1, the system was running his latest available software version at the time of study. Automated scripts were created to identify bone tissue and skin as a subtraction volume between bone and body. The soft tissue CT window was then manually used to increase or decrease the thickness of the skin, following the landmarks outlined in the protocol. The entire head scalp was defined as WScalp (WS), and a duplicate and reduced version was also defined as PCFScalp (PCFS). We randomly chose 40 patients to create both WS and PCF atlas with RayStation and 8 patients were used as testers for both volumes, the patients with major bone changes after neurosurgery were excluded. The contouring time was recorded, the mean time was calculated, and the contouring results were analyzed by experts. Standard similarity metrics of 3D DICE similarity coefficient and mean distance to agreement (MDA) were calculated. RESULTS A total of 52 patients were selected for the study, with a median contouring time of 19 minutes using the guidelines, the A_H protocol and automatic scripting. Three patients were excluded. Of the 8 testers, including both volumes (WS and PCFS), the mean contouring time for the expert operator was 17.5 min. While the contouring undergone by the automatic atlas was 11 min and the mean time of the expert correction was 4.5 min. Considering the work done by the atlas is in background, this resulted in a time savings of 80% for the operator. Table 1 contains mean and one standard deviation data for the metric, both WS and PCFS tested. CONCLUSION Atlas-based self-segmentation and the Alopecia_Hope protocol offer a more efficient and accurate method to identify specific areas of the scalp that may be affected by post-radiotherapy hair loss. This study demonstrates the effectiveness and efficiency in reducing radiotherapy workload and improving accuracy, with possible future application in the prevention of permanent alopecia and in improving the quality of life of patients undergoing whole brain radiotherapy.
Collapse
Affiliation(s)
- C Satragno
- Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy
| | - M Barboro
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy
| | | | | | - M Turazzi
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| | - S Campora
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| | - S E Cena
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| | - A Coco
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| | - D Esposito
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| | - A Ferrero
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| | - A Ginulla
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| | - S Mastrogiovanni
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| | - F Piciche
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| | - C Scaffidi
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| | - C Tominai
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| | - F Cavagnetto
- Medical physics unit, IRCCS Policlinico San Martino Hospital, Genoa, Italy
| | - D Zefiro
- Medical physics unit, IRCCS Policlinico San Martino Hospital, Genoa, Italy
| | - F Giannelli
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy
| | - S Barra
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy
| | - L Belgioia
- Radiation Oncology Department, IRCCS Policlinico San Martino Hospital, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
| |
Collapse
|
5
|
Rigogliuso S, Campora S, Notarbartolo M, Ghersi G. Recovery of Bioactive Compounds from Marine Organisms: Focus on the Future Perspectives for Pharmacological, Biomedical and Regenerative Medicine Applications of Marine Collagen. Molecules 2023; 28:molecules28031152. [PMID: 36770818 PMCID: PMC9920902 DOI: 10.3390/molecules28031152] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 01/05/2023] [Accepted: 01/17/2023] [Indexed: 01/27/2023] Open
Abstract
Marine environments cover more than 70% of the Earth's surface and are among the richest and most complex ecosystems. In terms of biodiversity, the ocean represents an important source, still not widely exploited, of bioactive products derived from species of bacteria, plants, and animals. However, global warming, in combination with multiple anthropogenic practices, represents a serious environmental problem that has led to an increase in gelatinous zooplankton, a phenomenon referred to as jellyfish bloom. In recent years, the idea of "sustainable development" has emerged as one of the essential elements of green-economy initiatives; therefore, the marine environment has been re-evaluated and considered an important biological resource. Several bioactive compounds of marine origin are being studied, and among these, marine collagen represents one of the most attractive bio-resources, given its use in various disciplines, such as clinical applications, cosmetics, the food sector, and many other industrial applications. This review aims to provide a current overview of marine collagen applications in the pharmacological and biomedical fields, regenerative medicine, and cell therapy.
Collapse
Affiliation(s)
- Salvatrice Rigogliuso
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
| | - Simona Campora
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
- Correspondence: (S.C.); (M.N.); Tel.: +39-091-238-62813 (S.C.); +39-091-238-97426 (M.N.)
| | - Monica Notarbartolo
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
- Correspondence: (S.C.); (M.N.); Tel.: +39-091-238-62813 (S.C.); +39-091-238-97426 (M.N.)
| | - Giulio Ghersi
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
- Abiel s.r.l., c/o Department STEBICEF, University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
| |
Collapse
|
6
|
Satragno C, Verrico A, Giannelli F, Ferrero A, Campora S, Turazzi M, Cavagnetto F, Schiavetti I, Garrè ML, Garibotto F, Milanaccio C, Piccolo G, Crocco M, Ramaglia A, Di Profio S, Barra S, Belgioia L. High dose craniospinal irradiation as independent risk factor of permanent alopecia in childhood medulloblastoma survivors: cohort study and literature review. J Neurooncol 2022; 160:659-668. [PMID: 36369416 PMCID: PMC9758075 DOI: 10.1007/s11060-022-04186-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2022] [Accepted: 10/28/2022] [Indexed: 11/13/2022]
Abstract
PURPOSE Our aim was to determine the main risk factors related to the occurrence of permanent alopecia in childhood medulloblastoma (MB) survivors. METHODS We retrospectively analyzed the clinical features of all consecutive MB survivors treated at our institute. We divided the patients into 3 groups depending on the craniospinal irradiation (CSI) dose received and defined permanent alopecia first in terms of the skin region affected (whole scalp and nape region), then on the basis of the toxicity degree (G). Any relationship between permanent alopecia and other characteristics was investigated by a univariate and multivariate analysis and Odds ratio (OR) with confidence interval (CI) was reported. RESULTS We included 41 patients with a mean10-year follow-up. High dose CSI resulted as an independent factor leading to permanent hair loss in both groups: alopecia of the whole scalp (G1 p-value 0.030, G2 p-value 0.003) and of the nape region (G1 p-value 0.038, G2 p-value 0.006). The posterior cranial fossa (PCF) boost volume and dose were not significant factors at multivariate analysis neither in permanent hair loss of the whole scalp nor only in the nuchal region. CONCLUSION In pediatric patients with MB, the development of permanent alopecia seems to depend only on the CSI dose ≥ 36 Gy. Acute damage to the hair follicle is dose dependent, but in terms of late side effects, constant and homogeneous daily irradiation of a large volume may have a stronger effect than a higher but focal dose of radiotherapy.
Collapse
Affiliation(s)
- C Satragno
- Dipartimento Di Medicina Sperimentale (DIMES), Università Degli Studi Di Genova, Via Leon Battista Alberti, 16132, Genova, GE, Italia.
| | - A Verrico
- Unità di Neuroncologia, IRCCS Istituto Giannina Gaslini, Genova, Italia
| | - F Giannelli
- UO Radioterapia Oncologica, IRCCS Ospedale Policlinico San Martino, Genova, Italia
| | - A Ferrero
- Dipartimento Di Medicina Sperimentale (DIMES), Università Degli Studi Di Genova, Via Leon Battista Alberti, 16132, Genova, GE, Italia
| | - S Campora
- Dipartimento di Scienza Della Salute (DISSAL), Università Degli Studi di Genova, Genova, Italia
| | - M Turazzi
- Dipartimento di Scienza Della Salute (DISSAL), Università Degli Studi di Genova, Genova, Italia
| | - F Cavagnetto
- UO Fisica Sanitaria, IRCCS Ospedale Policlinico San Martino, Genova, Italia
| | - I Schiavetti
- Dipartimento di Scienze Della Salute (DISSAL), Sezione di Biostatistica, Università Degli Studi di Genova, Genova, Italia
| | - M L Garrè
- Unità di Neuroncologia, IRCCS Istituto Giannina Gaslini, Genova, Italia
| | - F Garibotto
- Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica, Ginecologia e Pediatria (DINOGMI), Università Degli Studi di Genova, Genova, Italia
| | - C Milanaccio
- Unità di Neuroncologia, IRCCS Istituto Giannina Gaslini, Genova, Italia
| | - G Piccolo
- Unità di Neuroncologia, IRCCS Istituto Giannina Gaslini, Genova, Italia
- Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica, Ginecologia e Pediatria (DINOGMI), Università Degli Studi di Genova, Genova, Italia
| | - M Crocco
- Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica, Ginecologia e Pediatria (DINOGMI), Università Degli Studi di Genova, Genova, Italia
| | - A Ramaglia
- Unità di Neuroradiologia, IRCCS Istituto Giannina Gaslini, Genova, Italia
| | - S Di Profio
- Unità di Psicologia, IRCCS Istituto Giannina Gaslini, Genova, Italia
| | - S Barra
- UO Radioterapia Oncologica, IRCCS Ospedale Policlinico San Martino, Genova, Italia
| | - L Belgioia
- Dipartimento di Scienza Della Salute (DISSAL), Università Degli Studi di Genova, Genova, Italia
- UO Radioterapia Oncologica, IRCCS Ospedale Policlinico San Martino, Genova, Italia
| |
Collapse
|
7
|
Capuana E, Campora S, Catanzaro G, Lopresti F, Conoscenti G, Ghersi G, La Carrubba V, Brucato V, Pavia FC. Computational modeling and experimental characterization of fluid dynamics in micro-CT scanned scaffolds within a multiple-sample airlift perfusion bioreactor. Biochem Eng J 2022. [DOI: 10.1016/j.bej.2022.108797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
8
|
Piacenza E, Campora S, Carfì Pavia F, Chillura Martino DF, Laudicina VA, Alduina R, Turner RJ, Zannoni D, Presentato A. Tolerance, Adaptation, and Cell Response Elicited by Micromonospora sp. Facing Tellurite Toxicity: A Biological and Physical-Chemical Characterization. Int J Mol Sci 2022; 23:ijms232012631. [PMID: 36293484 PMCID: PMC9604092 DOI: 10.3390/ijms232012631] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 10/11/2022] [Accepted: 10/18/2022] [Indexed: 11/16/2022] Open
Abstract
The intense use of tellurium (Te) in industrial applications, along with the improper disposal of Te-derivatives, is causing their accumulation in the environment, where oxyanion tellurite (TeO32−) is the most soluble, bioavailable, and toxic Te-species. On the other hand, tellurium is a rare metalloid element whose natural supply will end shortly with possible economic and technological effects. Thus, Te-containing waste represents the source from which Te should be recycled and recovered. Among the explored strategies, the microbial TeO32− biotransformation into less toxic Te-species is the most appropriate concerning the circular economy. Actinomycetes are ideal candidates in environmental biotechnology. However, their exploration in TeO32− biotransformation is scarce due to limited knowledge regarding oxyanion microbial processing. Here, this gap was filled by investigating the cell tolerance, adaptation, and response to TeO32− of a Micromonospora strain isolated from a metal(loid)-rich environment. To this aim, an integrated biological, physical-chemical, and statistical approach combining physiological and biochemical assays with confocal or scanning electron (SEM) microscopy and Fourier-transform infrared spectroscopy in attenuated total reflectance mode (ATR-FTIR) was designed. Micromonospora cells exposed to TeO32− under different physiological states revealed a series of striking cell responses, such as cell morphology changes, extracellular polymeric substance production, cell membrane damages and modifications, oxidative stress burst, protein aggregation and phosphorylation, and superoxide dismutase induction. These results highlight this Micromonospora strain as an asset for biotechnological purposes.
Collapse
Affiliation(s)
- Elena Piacenza
- Department of Biological, Chemical and Pharmaceutical Science and Technologies, University of Palermo, Viale Delle Scienze, Ed. 16, 90128 Palermo, Italy
- Correspondence: (E.P.); (A.P.)
| | - Simona Campora
- Department of Biological, Chemical and Pharmaceutical Science and Technologies, University of Palermo, Viale Delle Scienze, Ed. 16, 90128 Palermo, Italy
| | - Francesco Carfì Pavia
- Department of Engineering, University of Palermo, Viale Delle Scienze, Ed. 8, 90128 Palermo, Italy
| | - Delia Francesca Chillura Martino
- Department of Biological, Chemical and Pharmaceutical Science and Technologies, University of Palermo, Viale Delle Scienze, Ed. 16, 90128 Palermo, Italy
| | - Vito Armando Laudicina
- Department of Agricultural, Food and Forest Sciences, University of Palermo, Viale Delle Scienze, Ed. 4, 90128 Palermo, Italy
| | - Rosa Alduina
- Department of Biological, Chemical and Pharmaceutical Science and Technologies, University of Palermo, Viale Delle Scienze, Ed. 16, 90128 Palermo, Italy
| | - Raymond Joseph Turner
- Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada
| | - Davide Zannoni
- Department of Pharmacy and Biotechnology, University of Bologna, Via Irnerio 42, 40126 Bologna, Italy
| | - Alessandro Presentato
- Department of Biological, Chemical and Pharmaceutical Science and Technologies, University of Palermo, Viale Delle Scienze, Ed. 16, 90128 Palermo, Italy
- Correspondence: (E.P.); (A.P.)
| |
Collapse
|
9
|
Campora S, Mohsen R, Passaro D, Samir H, Ashraf H, Al-Mofty SED, Diab AA, El-Sherbiny IM, Snowden MJ, Ghersi G. Functionalized Poly( N-isopropylacrylamide)-Based Microgels in Tumor Targeting and Drug Delivery. Gels 2021; 7:gels7040203. [PMID: 34842694 PMCID: PMC8628686 DOI: 10.3390/gels7040203] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 10/27/2021] [Accepted: 11/04/2021] [Indexed: 11/16/2022] Open
Abstract
Over the past several decades, the development of engineered small particles as targeted and drug delivery systems (TDDS) has received great attention thanks to the possibility to overcome the limitations of classical cancer chemotherapy, including targeting incapability, nonspecific action and, consequently, systemic toxicity. Thus, this research aims at using a novel design of Poly(N-isopropylacrylamide) p(NIPAM)-based microgels to specifically target cancer cells and avoid the healthy ones, which is expected to decrease or eliminate the side effects of chemotherapeutic drugs. Smart NIPAM-based microgels were functionalized with acrylic acid and coupled to folic acid (FA), targeting the folate receptors overexpressed by cancer cells and to the chemotherapeutic drug doxorubicin (Dox). The successful conjugation of FA and Dox was demonstrated by dynamic light scattering (DLS), Fourier-transform infrared (FTIR) spectroscopy, thermogravimetric analysis (TGA), UV-VIS analysis, and differential scanning calorimetry (DSC). Furthermore, viability assay performed on cancer and healthy breast cells, suggested the microgels’ biocompatibility and the cytotoxic effect of the conjugated drug. On the other hand, the specific tumor targeting of synthetized microgels was demonstrated by a co-cultured (healthy and cancer cells) assay monitored using confocal microscopy and flow cytometry. Results suggest successful targeting of cancer cells and drug release. These data support the use of pNIPAM-based microgels as good candidates as TDDS.
Collapse
Affiliation(s)
- Simona Campora
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (S.C.); (D.P.)
- Abiel s.r.l, c/o Arca Incubatore di Imprese, University of Palermo, Viale delle Scienze, Ed. 16 (Floor-2), 90128 Palermo, Italy
| | - Reham Mohsen
- Faculty of Biotechnology, October University for Modern Sciences and Arts, Cairo 12451, Egypt; (R.M.); (H.S.); (H.A.); (A.A.D.)
- School of Science, University of Greenwich, Gillingham, Chatham, Kent, Canterbury ME4 4TB, UK;
| | - Daniel Passaro
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (S.C.); (D.P.)
| | - Howida Samir
- Faculty of Biotechnology, October University for Modern Sciences and Arts, Cairo 12451, Egypt; (R.M.); (H.S.); (H.A.); (A.A.D.)
| | - Hesham Ashraf
- Faculty of Biotechnology, October University for Modern Sciences and Arts, Cairo 12451, Egypt; (R.M.); (H.S.); (H.A.); (A.A.D.)
| | - Saif El-Din Al-Mofty
- Center of Materials Science, Zewail City of Science and Technology, 6th October City, Giza 12588, Egypt; (S.E.-D.A.-M.); (I.M.E.-S.)
| | - Ayman A. Diab
- Faculty of Biotechnology, October University for Modern Sciences and Arts, Cairo 12451, Egypt; (R.M.); (H.S.); (H.A.); (A.A.D.)
| | - Ibrahim M. El-Sherbiny
- Center of Materials Science, Zewail City of Science and Technology, 6th October City, Giza 12588, Egypt; (S.E.-D.A.-M.); (I.M.E.-S.)
| | - Martin J. Snowden
- School of Science, University of Greenwich, Gillingham, Chatham, Kent, Canterbury ME4 4TB, UK;
| | - Giulio Ghersi
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (S.C.); (D.P.)
- Abiel s.r.l, c/o Arca Incubatore di Imprese, University of Palermo, Viale delle Scienze, Ed. 16 (Floor-2), 90128 Palermo, Italy
- Correspondence:
| |
Collapse
|
10
|
Salamone M, Rigogliuso S, Nicosia A, Campora S, Bruno CM, Ghersi G. 3D Collagen Hydrogel Promotes In Vitro Langerhans Islets Vascularization through ad-MVFs Angiogenic Activity. Biomedicines 2021; 9:biomedicines9070739. [PMID: 34199087 PMCID: PMC8301445 DOI: 10.3390/biomedicines9070739] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Revised: 06/22/2021] [Accepted: 06/24/2021] [Indexed: 02/07/2023] Open
Abstract
Adipose derived microvascular fragments (ad-MVFs) consist of effective vascularization units able to reassemble into efficient microvascular networks. Because of their content in stem cells and related angiogenic activity, ad-MVFs represent an interesting tool for applications in regenerative medicine. Here we show that gentle dissociation of rat adipose tissue provides a mixture of ad-MVFs with a length distribution ranging from 33–955 μm that are able to maintain their original morphology. The isolated units of ad-MVFs that resulted were able to activate transcriptional switching toward angiogenesis, forming tubes, branches, and entire capillary networks when cultured in 3D collagen type-I hydrogel. The proper involvement of metalloproteases (MMP2/MMP9) and serine proteases in basal lamina and extracellular matrix ECM degradation during the angiogenesis were concurrently assessed by the evaluation of alpha-smooth muscle actin (αSMA) expression. These results suggest that collagen type-I hydrogel provides an adequate 3D environment supporting the activation of the vascularization process. As a proof of concept, we exploited 3D collagen hydrogel for the setting of ad-MVF–islet of Langerhans coculture to improve the islets vascularization. Our results suggest potential employment of the proposed in vitro system for regenerative medicine applications, such as the improving of the islet of Langerhans engraftment before transplantation.
Collapse
Affiliation(s)
- Monica Salamone
- Abiel s.r.l., c/o Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF) University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (M.S.); (S.R.); (C.M.B.)
| | - Salvatrice Rigogliuso
- Abiel s.r.l., c/o Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF) University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (M.S.); (S.R.); (C.M.B.)
| | - Aldo Nicosia
- Institute for Biomedical Research and Innovation-National Research Council (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy;
| | - Simona Campora
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF) University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy;
| | - Carmelo Marco Bruno
- Abiel s.r.l., c/o Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF) University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (M.S.); (S.R.); (C.M.B.)
| | - Giulio Ghersi
- Abiel s.r.l., c/o Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF) University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (M.S.); (S.R.); (C.M.B.)
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF) University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy;
- Correspondence:
| |
Collapse
|
11
|
Salamone M, Rigogliuso S, Nicosia A, Tagliavia M, Campora S, Cinà P, Bruno C, Ghersi G. Neural Crest-Derived Chondrocytes Isolation for Tissue Engineering in Regenerative Medicine. Cells 2020; 9:cells9040962. [PMID: 32295228 PMCID: PMC7226976 DOI: 10.3390/cells9040962] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 04/07/2020] [Accepted: 04/07/2020] [Indexed: 01/04/2023] Open
Abstract
Chondrocyte transplantation has been successfully tested and proposed as a clinical procedure aiming to repair articular cartilage defects. However, the isolation of chondrocytes and the optimization of the enzymatic digestion process, as well as their successful in vitro expansion, remain the main challenges in cartilage tissue engineering. In order to address these issues, we investigated the performance of recombinant collagenases in tissue dissociation assays with the aim of isolating chondrocytes from bovine nasal cartilage in order to establish the optimal enzyme blend to ensure the best outcomes of the overall procedure. We show, for the first time, that collagenase H activity alone is required for effective cartilage digestion, resulting in an improvement in the yield of viable cells. The extracted chondrocytes proved able to grow and activate differentiation/dedifferentiation programs, as assessed by morphological and gene expression analyses.
Collapse
Affiliation(s)
- Monica Salamone
- Abiel s.r.l, c/o University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (M.S.); (S.R.); (S.C.); (P.C.); (C.B.)
| | - Salvatrice Rigogliuso
- Abiel s.r.l, c/o University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (M.S.); (S.R.); (S.C.); (P.C.); (C.B.)
| | - Aldo Nicosia
- Institute for Biomedical Research and Innovation-National Research Council (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy; (A.N.); (M.T.)
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies [STEBICEF], University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
| | - Marcello Tagliavia
- Institute for Biomedical Research and Innovation-National Research Council (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy; (A.N.); (M.T.)
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies [STEBICEF], University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
| | - Simona Campora
- Abiel s.r.l, c/o University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (M.S.); (S.R.); (S.C.); (P.C.); (C.B.)
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies [STEBICEF], University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
| | - Paolo Cinà
- Abiel s.r.l, c/o University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (M.S.); (S.R.); (S.C.); (P.C.); (C.B.)
| | - Carmelo Bruno
- Abiel s.r.l, c/o University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (M.S.); (S.R.); (S.C.); (P.C.); (C.B.)
| | - Giulio Ghersi
- Abiel s.r.l, c/o University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy; (M.S.); (S.R.); (S.C.); (P.C.); (C.B.)
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies [STEBICEF], University of Palermo, Viale delle Scienze, Ed. 16, 90128 Palermo, Italy
- Correspondence:
| |
Collapse
|
12
|
Monti M, Campora S, Pirondi S, Gentili G, Guarrera A, Taverniti C, Cagnazzo C. New rules for clinical trials: who will play the game? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx436.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Cagnazzo C, Campora S, Pirondi S, Guarrera A, Nuzzo A, Gentili G, Taverniti C, Manuela M, Filippi R. Burnout syndrome: What impact on clinical research? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx384.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Cagnazzo C, Campora S, Pirondi S, Gentili G, Guarrera A, Taverniti C, Manuela M. Academic clinical research: Enough players to get out there? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx385.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Cagnazzo C, Campora S, Ferretti E, Arizio F, Marchesi E. New European Clinical Trial Regulation: perception and expectations in Italy. Ann Oncol 2017; 28:1648-1654. [PMID: 28368461 DOI: 10.1093/annonc/mdx153] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Indexed: 11/12/2022] Open
Abstract
Background In July 2012, the European Commission formalized the proposal for a European Clinical Trial Regulation that should replace the European Clinical Trials Directive 2001/20/CE. The new Regulation 536/2014 entered into force in June 2014 and it was expected to be applied not earlier than May 2016. Indeed, at the time, all required central tools are not yet available and new forecasts indicate it will become effective at the end of 2018. The aims of the Regulation are the promotion of higher standards in patient's safety and increasing transparency in Clinical Trials, also by changing the application process. Methods An online survey was conducted among the Italian's Clinical Research Coordinators and Clinical Investigators to examine the perception and knowledge about the upcoming changes in Clinical Trials. A total of 190 Clinical Research Coordinators and 80 Clinical Investigators were surveyed. Results Clinicians are less aware of the content of the Regulation than Clinical Research Coordinators, who demonstrate an extensive expertise on the topic (84.4%), mainly reached through self-training. The majority of the Investigators (74%) believes that their site's facilities and staff already met all the requirements imposed by the Regulation while Clinical Research Coordinators are less optimistic: 65.2% of them believes that the site staff is not yet fully aware of changes associated to its implementation. Conclusions The general opinion of the interviewed is that the new Regulation will strongly affect the trial management regardless of their type and phase, and the fulfillment of the imposed requirements represents an opportunity that Italy should not miss to increase its attractiveness to the pharmaceutical market.
Collapse
Affiliation(s)
- C Cagnazzo
- Medical Oncology, Candiolo Cancer Institute, Candiolo
| | | | - E Ferretti
- Multi-Specialists and Transplants, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano
| | - F Arizio
- Oncology Department, AUO San Luigi Gonzaga, Orbassano
| | - E Marchesi
- Chemotherapy Unit, Istituto Ortopedico Rizzoli, via Pupilli, 1, 40136 Bologna, Italy
- Italian Sarcoma Group, Bologna, Italy
| |
Collapse
|
16
|
Brain E, Corradengo D, Oriana N, Piccardo A, Matteucci F, Cortes J, Harbeck N, Würstlein R, Piris A, Alberini JL, Merlo DF, Degenhardt T, Turbiez I, Madar O, Monti M, Cesaro A, Rivitti E, Rollandi GA, Iacozzi M, Campazzi E, Campora S, Camporese D, Gennari A. Abstract OT3-03-03: Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot3-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The activation of international non-profit clinical trials funded by the European Commission (EC) is challenging given the cross-borders regulations and the need to follow specific timelines according to EC rules. We report here the logistic procedures and challenges faced by 4 academic centres from 4 different countries from the European Union (EU) for the activation of such program in metastatic breast cancer (MBC).
Materials and Methods
The primary objective of the ET-FES program is to validate the use of a new radiotracer 18F Fluoroestradiol (FES), targeting estrogen receptors, as a tool to better predict endocrine responsiveness in MBC, with PET/CT. The trial is sponsored by EO Galliera (Genoa, Italy) and brings together Italy, Spain, France and Germany. In 10/2012, ET-FES was approved for funding from EC under the Seventh Framework Programme after the first ERA-NET TRANSCAN Joint Transnational Call (JTC) for Proposals (2011) on validation of new biomarkers for personalized cancer medicine.
Results
The official start of the program was set up on 06/2013 by the Italian Ministry of Health. Time to institutional review board and to competent authority (CA) approvals were 1.5 and 11, 2 and 5, 3 and 16, and 13 and 14+ months in Italy, France, Spain and Germany respectively. Overall, no blocking comment was raised by the ethical committees; only minor clinical and methodological issues were raised in Germany and Spain. Issues from CA were raised in all countries except France (12, 21 and 23 queries in Italy, Spain and Germany respectively), on quality aspects of 18F-FES investigational medicinal product dossier. At the sponsor level, time to final agreement signature with Advanced Accelerator Applications, the 18F-FES manufacturing company, required 13 months. First patient could be enrolled in Italy 14 and 22 months after ethical committee approval and after the official start of the ET-FES project respectively.
Conclusions
As of May 2016, of 310 patients expected, only 28 have been enrolled from Italy. From a regulatory viewpoint and acknowledging that 18F-FES does not have yet any marketing approval in the EU, the ET-FES program approval process was timely completed at the ethical committee level in Italy, France and Spain. Time to CA approval varied across countries and was timely achieved only in France, due to requirements varying from CA to CA, stressing the serious lack of harmonized procedures although intended by the 2001/20/EC directive. Regarding sponsor's responsibilities (i.e. Italy), the administrative procedures needed to activate this type of EU projects remain critical, appealing for more tolerant time span in order to satisfy all the legal aspects on contracts by public bodies, according to national rules and laws. One needs to be very conscious of these timelines when applying to EU/EC calls, especially when the time allowed for the conduction of research is limited (3 years here), unless jeopardizing the entire multicentre and multinational effort.
Citation Format: Brain E, Corradengo D, Oriana N, Piccardo A, Matteucci F, Cortes J, Harbeck N, Würstlein R, Piris A, Alberini J-L, Merlo DF, Degenhardt T, Turbiez I, Madar O, Monti M, Cesaro A, Rivitti E, Rollandi GA, Iacozzi M, Campazzi E, Campora S, Camporese D, Gennari A. Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011 [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-03-03.
Collapse
Affiliation(s)
- E Brain
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - D Corradengo
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - N Oriana
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - A Piccardo
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - F Matteucci
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - J Cortes
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - N Harbeck
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - R Würstlein
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - A Piris
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - J-L Alberini
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - DF Merlo
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - T Degenhardt
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - I Turbiez
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - O Madar
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - M Monti
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - A Cesaro
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - E Rivitti
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - GA Rollandi
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - M Iacozzi
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - E Campazzi
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - S Campora
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - D Camporese
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - A Gennari
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| |
Collapse
|
17
|
Adamo G, Grimaldi N, Campora S, Bulone D, Bondì ML, Al-Sheikhly M, Sabatino MA, Dispenza C, Ghersi G. Multi-Functional Nanogels for Tumor Targeting and Redox-Sensitive Drug and siRNA Delivery. Molecules 2016; 21:molecules21111594. [PMID: 27886088 PMCID: PMC6274332 DOI: 10.3390/molecules21111594] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Revised: 10/18/2016] [Accepted: 11/16/2016] [Indexed: 02/08/2023] Open
Abstract
(1) Background: A new family of nanosystems able to discern between normal and tumor cells and to release a therapeutic agent in controlled way were synthetized by e-beam irradiation. This technique permits to obtain biocompatible, sterile, carboxyl-functionalized polyvinylpyrrolidone (PVP-co-acrylic acid) nanogels (NGs); (2) Methods: Here, we performed a targeting strategy based on the recognition of over-expressed proteins on tumor cells, like the folate receptor. The selective targeting was demonstrated by co-culture studies and flow cytometry analysis, using folate conjugated NGs. Moreover, nanoparticles were conjugated to a chemotherapeutic drug or to a pro-apoptotic siRNA through a glutathione sensitive spacer, in order to obtain a controlled release mechanism, specific for cancer cells. The drug efficiency was tested on tumor and healthy cells by flow cytometric analysis, confocal and epifluorescence microscopy and cytotoxicity assay; the siRNA effect was investigated by RNAi experiment; (3) Results: The data obtained showed that the use of NGs permits a faster cargo release in cancer cells, in response to high cytosolic glutathione level, also improving their efficacy; (4) Conclusion: The possibility of releasing biological molecules in a controlled way and to recognize a specific tumor target allows overcoming the typical limits of the classic cancer therapy.
Collapse
Affiliation(s)
- Giorgia Adamo
- Dipartimento di Scienze e Tecnologie Molecolari e Biomolecolari, Università degli Studi di Palermo, Viale delle Scienze, Edificio 16, 90128 Palermo, Italy.
| | - Natascia Grimaldi
- Dipartimento di Ingegneria Chimica, Gestionale, Informatica, Meccanica, Università degli Studi di Palermo, Viale delle Scienze, Edificio 6, 90128 Palermo, Italy.
| | - Simona Campora
- Dipartimento di Scienze e Tecnologie Molecolari e Biomolecolari, Università degli Studi di Palermo, Viale delle Scienze, Edificio 16, 90128 Palermo, Italy.
| | - Donatella Bulone
- Consiglio Nazionale delle Ricerche (CNR)-Istituto di Biofisica (IBF) UOS Palermo, Via U. La Malfa 153, 90146 Palermo, Italy.
| | - Maria Luisa Bondì
- Consiglio Nazionale delle Ricerche (CNR)-Istituto per lo Studio dei Materiali Nanostrutturati (ISMN) UOS Palermo, Via Ugo La Malfa, 153, 90146 Palermo, Italy.
| | - Mohamad Al-Sheikhly
- Department of Materials Science and Engineering, University of Maryland, College Park, MD 20742, USA.
| | - Maria Antonietta Sabatino
- Dipartimento di Ingegneria Chimica, Gestionale, Informatica, Meccanica, Università degli Studi di Palermo, Viale delle Scienze, Edificio 6, 90128 Palermo, Italy.
| | - Clelia Dispenza
- Dipartimento di Ingegneria Chimica, Gestionale, Informatica, Meccanica, Università degli Studi di Palermo, Viale delle Scienze, Edificio 6, 90128 Palermo, Italy.
| | - Giulio Ghersi
- Dipartimento di Scienze e Tecnologie Molecolari e Biomolecolari, Università degli Studi di Palermo, Viale delle Scienze, Edificio 16, 90128 Palermo, Italy.
| |
Collapse
|
18
|
Cagnazzo C, Campora S, Arizio F, Marchesi E. The new European Clinical Trial Regulation: Perception and expectations in Italy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw366.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Mcmahon L, Cagnazzo C, Campora S, Frati P. Phase I cancer clinical trials in Italy: state of the art and future challenges. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw345.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Cagnazzo C, Nanni O, Campora S, Frati P, Camisa R, Contu M, Sottile R, Canzanella G, McMahon L, Arizio F, Cinefra M. Clinical Trial Units in Italy: the perception of the Clinical Research Coordinators. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw345.16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Marchesi E, Monti M, Campora S, Gentili G, Frati P, Pirondi S, Taverniti C, Cagnazzo C. AIFA Determination 809/2015 on Phase I Clinical Trials: a new challenge for Italian Research. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw345.18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
22
|
Monti M, Corradengo D, Nanni O, Piccardo A, Matteucci F, Brain E, Cortes J, Harbeck N, Wuerstlein R, Piris A, Merlo D, Degenhardt T, Cesario A, Rivitti E, Rollandi G, Iacozzi M, Campazzi E, Campora S, Camporese D, Gennari A. ERA-Net TRANSCAN JTC 2011: Critical aspects of the startup procedures of an International Academic Clinical trial (ET-FES), funded by the European Community (EC) and coordinated by an Italian Institution. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw345.22] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Lanzalaco S, Campora S, Brucato V, Carfì Pavia F, Di Leonardo ER, Ghersi G, Scialdone O, Galia A. Sterilization of macroscopic poly(l-lactic acid) porous scaffolds with dense carbon dioxide: Investigation of the spatial penetration of the treatment and of its effect on the properties of the matrix. J Supercrit Fluids 2016. [DOI: 10.1016/j.supflu.2016.01.014] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
24
|
Mauro N, Campora S, Adamo G, Scialabba C, Ghersi G, Giammona G. Polyaminoacid–doxorubicin prodrug micelles as highly selective therapeutics for targeted cancer therapy. RSC Adv 2016. [DOI: 10.1039/c6ra14935a] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
An amphiphilic copolymer carrying high-dose doxorubicin (21% on a weight basis), PHEA–EDA–P,C–Doxo, was prepared by coupling doxorubicin with a biocompatible polyaminoacid through a pH-sensitive spacer.
Collapse
Affiliation(s)
- N. Mauro
- Laboratory of Biocompatible Polymers
- Department of Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF)
- University of Palermo
- 32 90123 Palermo
- Italy
| | - S. Campora
- Department of Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF)
- University of Palermo
- 16 90128 Palermo
- Italy
| | - G. Adamo
- Department of Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF)
- University of Palermo
- 16 90128 Palermo
- Italy
| | - C. Scialabba
- Laboratory of Biocompatible Polymers
- Department of Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF)
- University of Palermo
- 32 90123 Palermo
- Italy
| | - G. Ghersi
- Department of Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF)
- University of Palermo
- 16 90128 Palermo
- Italy
| | - G. Giammona
- Laboratory of Biocompatible Polymers
- Department of Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF)
- University of Palermo
- 32 90123 Palermo
- Italy
| |
Collapse
|
25
|
Campora S, Arizio F, Ferretti E, Morabito S, Taverniti C, Marchetti F, Dall'Agata M, Frati P, McMahon L, Ragazzini A, Cagnazzo C. New european clinical trials regulation: perception and expectations in Italy. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
26
|
Mauro N, Campora S, Scialabba C, Adamo G, Licciardi M, Ghersi G, Giammona G. Self-organized environment-sensitive inulin–doxorubicin conjugate with a selective cytotoxic effect towards cancer cells. RSC Adv 2015. [DOI: 10.1039/c5ra00287g] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
An inulin-based copolymer bearing high dose doxorubicin (18.45 % w/w), INU-EDA-P,C-DOXO, was prepared by coupling doxorubicin with inulin though citraconylamide bridge used as pH sensitive spacer. Its smart and selective anticancer effect was proved.
Collapse
Affiliation(s)
- N. Mauro
- Laboratory of Biocompatible Polymers
- Department of “Scienze e Tecnologie Biologiche
- Chimiche e Farmaceutiche” (STEBICEF)
- University of Palermo
- 32 90123 Palermo
| | - S. Campora
- Department of “Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche” (STEBICEF)
- University of Palermo
- 16 90128 Palermo
- Italy
| | - C. Scialabba
- Laboratory of Biocompatible Polymers
- Department of “Scienze e Tecnologie Biologiche
- Chimiche e Farmaceutiche” (STEBICEF)
- University of Palermo
- 32 90123 Palermo
| | - G. Adamo
- Department of “Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche” (STEBICEF)
- University of Palermo
- 16 90128 Palermo
- Italy
| | - M. Licciardi
- Laboratory of Biocompatible Polymers
- Department of “Scienze e Tecnologie Biologiche
- Chimiche e Farmaceutiche” (STEBICEF)
- University of Palermo
- 32 90123 Palermo
| | - G. Ghersi
- Department of “Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche” (STEBICEF)
- University of Palermo
- 16 90128 Palermo
- Italy
| | - G. Giammona
- Laboratory of Biocompatible Polymers
- Department of “Scienze e Tecnologie Biologiche
- Chimiche e Farmaceutiche” (STEBICEF)
- University of Palermo
- 32 90123 Palermo
| |
Collapse
|
27
|
DeCensi A, Piccardo A, Altrinetti V, Bacigalupo L, Biscaldi E, Bianchi P, Barbera F, Cabria M, Camti C, Zanardi S, Campora S, Puntoni M, Rollandi GA, Villavecchia G. E. Abstract P2-05-01: A Comparative Study of 18F-Fluoride PET/CT and Whole-Body High Resolution CT (HRCT) for the Detection of Bone Metastases in Patients with Advanced Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-05-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Bone scintigraphy (BS) have been shown to be of value in detecting bone metastases several months before conventional radiography, whereas computed tomography (HRCT) and magnetic resonance imaging (MRI) can reveal more metastases in the spine than conventional BS. 18F-Fluoride PET has been shown to be more accurate than BS for the detection bone lesions in different malignancies and has been suggested as an alternative to BS. Recent studies have shown that integrated 18F-Fluoride-PET/CT is both sensitive and specific for detection of lytic and sclerotic lesions and is superior to 18F-Fluoride PET. The aim of our study is to evaluate the diagnostic accuracy of 18F-Fluoride-PET/CT in comparison to HRCT for the detection of bone metastases in breast cancer patients.
Material and methods: The study involved 39 patients with breast cancer with known bone metastases or at high risk for its presence. All patients presented indications for skeletal surveys. Imaging was performed on an integrated PET/CT system. All PET scans were acquired in 2D mode and were reconstructed using an iterative reconstruction algorithm; diagnostic HRCT data of PET/CT were acquired for detecting bone lesions and were used for attenuation correction. PET acquisition started 60 min after intravenous injection of 370-550 MBq 18F-labelled NaF and included 10-12 bed positions.
The interpretation of PET/CT and High resolution CT studies was made as a consensus reading of two nuclear medicine physicians and a radiologist who had access to clinical, as well as previous radiological imaging information. 12 months follow-up based on previous and/or following imaging studies was considered the gold standard. Results: Overall 671 bone lesions were detected in our analysis including both PET/CT and CT results. Of these lesions 530 malignant, 32 equivocal and 109 benign were classified by consensus reading. 18F-Fluoride PET/CT detected 491 bone metastases, 114 (23%) of which without any clear morphological changes on CT. HRCT detected 416 bone metastases, 39 (9.3%) of which without any 18F-fluoride uptake. The overall sensitivity and specificity was 90% and 91% for 18F-Fluoride-PET/CT and 79 and 93% for HRCT, respectively. In a patients based analysis both 18F-Fluoride-PET/CT and HRCT identified the same number of patients with bone metastases (27 of 39).
Conclusions: Our data show a high agreement (71% of lesions and 100% of the patients) between 18F-Fluoride-PET/CT and HRCT for bone metastases detection. However integrated analysis of 18F-Fluoride-PET/HRCT has the best diagnostic option to evaluate bone involvement in breast cancer, and 18F-Fluoride-PET/CT seems to have the highest sensitivity. Follow-up is ongoing to assess the prognostic/predictive value of 18F-Fluoride-PET/CT.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-05-01.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - M Cabria
- Ospedali Galliera, Genova, Italy
| | - C Camti
- Ospedali Galliera, Genova, Italy
| | | | | | | | | | | |
Collapse
|